loader2
Partner With Us NRI

Company details

133.85
136.50
121.35
299.90
6M Return -25.96%
1Y Return -53.86%
Mkt Cap.(Cr) 823.83
Volume 36
Div Yield 0.00%
OI
-
OI Chg %
-
Volume 36

Open Free Demat Account Online with ICICIDIRECT

SWOT

  • swot

  • technicals

  • deals

  • shareholding


EMA SMA

Delivery and volume

Financials

  • Profit and loss statement

  • Balance sheet

  • Quarterly Result

  • Ratio

Sales(Cr.)

Operating Profit(Cr.)

Profit after Tax(Cr.)

Equity

Reserves and Surplus

Debt

Sales

Operating Profit

Profit after tax

PE

Debt/Equity

P BV

INSIDER & INSTITUIONAL ACTIVITY

Equity Capital: 827.14 Cr FV: 1.00
Period MF Net Purchase / (sold) FII Net
LAST 1M 3,213.79 10,702.06
LAST 3M 4,765.78 66,293.35
LAST 6M 78,132.76 -40,125.32
LAST 12M 202,528.75 -192,001.24
  • Announcement
  • Corporate action
  • No Data Found

Date Action Type Ratio
No data found

Information

  • About Company
  • Company Info
  • Listing Info
0
73.59%
135.0413
-5.18%
-63.73%
Description
  • India`s leading research-based health management company with established research, manufacturing and marketing capabilities are collectively known as Panacea Biotec Limited (PBL), which was incorporated on 2nd February 1984 under the name of Panacea Drug (P) Ltd. A second largest vaccine producer in India has the product portfolio of highly innovative prescription products in important therapeutic areas such as pain management, diabetes management, renal-disease management, anti-osteoporosis, anti-tubercular, gastro-intestinal care products and vaccines. The Company has collaborations and tie-ups with leading national and international research organizations and corporations. PBL has ultra modern, state-of-art production facilities at Himachal Pradesh, Punjab & Delhi for manufacturing vaccines and pharmaceutical formulations comply with the US-FDA, UK-MHRA, SAMCC and WHO-cGMP standards and it has four research and development centers. The Company also has 24 product patents, valid in more than 60 countries worldwide. The plant for vaccines production (Radicura Pharma) and pharmaceutical formulations plant (Panacea Drug P Ltd) at New Delhi were established during the year 1988 and 1989 respectively. In 1993, merger of Panacea Drugs (P) Ltd and Radicura Pharma gave the name Panacea Biotec Ltd. The Company made its Initial Public Offering (IPO) in the year of 1995 and also in the same year, PBL had formed state -of the- art Drug Delivery R&D centre at Lalru. In the year 1997, the company obtained its first product patent in several countries. PBL`s Research & Development made a tie up with European MNC in the year 2001 and in 2002, an in-licensing agreement was made with Biotechnology Consortium of India for development & commercialization of Anthrax Vaccine. Also in the identical year of 2002, the company had commissioned Recombinant Vaccine production plant. During the year 2004, PBL made an in-licensing agreement with National Institute of Immunology, New Delhi, for Japanese Encephalitis Candidate Vaccine, marketing joint venture with Chiron (now Novartis) Vaccines, UK and also made collaboration with Cambridge Bio-stability, UK, for Thermo Stable Vaccines. After a year in 2005, an in-licensing agreement was prepared with National Institute of Health, USA for Hair Growth Hormone. During the year 2006, ultra modern Pharmaceuticals formulation facility at Baddi, Himachal Pradesh was goes live, which has WHO cGMP complaint. Landmark collaborations were made with The Netherlands Vaccine Institute (The Nederlands Vaccin Institute (NVI)) for manufacture & marketing of finished Inactivated Polio Vaccine (IPV) and a number of IPV based combination vaccines in India and across the globe. Collaboration was happened with PT.Bio Farma to manufacture & market Measles Vaccine. Also in the same year of 2006, the company had inaugurated its Biopharmaceutical R&D Centre at New Delhi and made collaboration with National Research Development Corporation (NRDC) for technology transfer of Foot and Mouth Vaccine. Vaccine Formulation Plant of the company was established at Baddi in the year 2007 and the research agreement was made with Punjab University to develop New Chemical Entities for Psychiatric Disorders. PBL forayed into Healthcare Delivery in the year 2008, made a collaboration to set-up 220 bed multi super-specialty hospital in NCR and also the company obtained a patent (Patent No. 7,371,412 B2) from US Patent & Trademark Office for the product Thank GodTM (Euphorbia Prostrata) for effective management of hemorrhoids & piles in the identical year of 2008.

Read More

Registered Address

Ambala-Chandigarh Highway, , Lalru, Punjab, 140501

Tel : 91-1762-505900
Email : companysec:panaceabiotec.com
Website : http://www.panaceabiotec.com

Registrar

Skyline Financial Services Pvt

AGM Date (Month) : Sep
Face Value Equity Shares : 1
Market Lot Equity Shares : 1
BSE Code : 531349
NSE Code : PANACEABIO
Book Closure Date (Month) : Sep
BSE Group : B
ISIN : INE922B01023

ICICIdirect Panacea Biotec Ltd FAQ

You can buy Panacea Biotec Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Panacea Biotec Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of Sep 26, 2022 09:37 AM the closing price of Panacea Biotec Ltd was ₹ 134.50.
Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Sep 26, 2022 09:37 AM, the market cap of Panacea Biotec Ltd stood at ₹ 823.83.
The latest PE ratio of Panacea Biotec Ltd as of Sep 26, 2022 09:37 AM is 0
The latest PB ratio of Panacea Biotec Ltd as of Sep 26, 2022 09:37 AM is 0.99
The 52-week high of Panacea Biotec Ltd is ₹ 299.90 while the 52-week low is ₹ 121.35 .

Thank you for subscribing to Equity/ Equity Research/MF/FnO Newsletter. You will hear from us shortly.

for your vote

CLOSE